Key Highlights

  • Revenue was USD 12.7 million against a USD 11.71 million estimate, and EPS of USD -0.06 against USD -0.07.
  • 2026 Revenue guidance rose to USD 46 million to USD 48 million, with free cash outflow under USD 8 million.
  • Clinical Solutions revenue was USD 3.2 million, up 86%, while Lab Essentials revenue was USD 9.0 million, up 9%.
  • The company closed a USD 46.0 million public offering in October 2026, with net proceeds near USD 42.9 million.

Alpha Teknova, Inc. (NASDAQ:TKNO) paired its third quarter results with a higher revenue outlook for 2026. The company now guides to total revenue of USD 46 million to USD 48 million for the year ending December 31, 2026, and it reaffirmed free cash outflow of less than USD 8 million. Management described the quarter as a second consecutive period of record revenue.

Guidance and the October Offering

On October 22, 2026, the company closed an underwritten public offering of 9,200,000 shares at USD 5.00 per share, including the full exercise of the underwriters' option. Gross proceeds were USD 46.0 million and net proceeds were approximately USD 42.9 million. The chief financial officer said the raise gave the company Balance Sheet flexibility and added a significant number of new investors.

Management is scheduled to attend investor conferences on November 17 and November 18, 2026.

The Quarter in Detail

Revenue was USD 12.7 million, up 22% from USD 10.5 million a year earlier. Gross Profit was USD 4.8 million, with gross Margin of 38.0% against 30.7%. The company attributed the margin change mainly to higher revenue and, to a lesser extent, lower Fixed Cost absorption into Cost of Goods Sold from changes in finished goods inventory levels, partly offset by higher variable costs.

Operating expenses were USD 8.0 million against USD 7.2 million, which the company tied to higher sales and Marketing spending on added headcount, slightly higher general and administrative costs and lower stock-based compensation. Loss from operations was USD 3.2 million against USD 4.0 million. Net loss was USD 3.5 million, or USD 0.06 per diluted share, against USD 4.3 million, or USD 0.08.

Adjusted EBITDA was negative USD 1.0 million against negative USD 1.6 million. Cash used in Operating Activities was USD 1.3 million against USD 2.0 million, and free cash outflow was USD 1.4 million against USD 2.4 million.

Segments, Customers and Products

Lab Essentials revenue was USD 9.0 million against USD 8.3 million, and Clinical Solutions revenue was USD 3.2 million against USD 1.7 million. Other revenue was USD 0.5 million. For nine months, total revenue was USD 35.97 million against USD 30.54 million.

Chief executive Stephen Gunstream attributed growth to higher sales to life science tools and diagnostics customers and to biopharma customers. He noted more purchases of custom products by small and mid-sized biotech customers and their contract manufacturers, which he said the company believes is an early indication of improved biotech funding over the past four quarters.

The company also launched the Fill-Tek Dispensing System, which lets customers order specific single-use bag sizes, quantities and Fill volumes across RUO, RUO+ and GMP grades with no added turnaround time.

Quarter in Numbers

Revenue of USD 12.7 million sits alongside a net loss of USD 3.5 million, cash and short-term investments of USD 16.6 million and total borrowings of USD 13.2 million at September 30. Those balances predate the October offering, which added net proceeds of approximately USD 42.9 million.

Management named full year revenue guidance of USD 46 million to USD 48 million and free cash outflow below USD 8 million. The dated items are the October 22 offering close and the two investor conferences on November 17 and 18.